亞盛醫藥-B(06855.HK)推進單藥或聯合治療晚期 ER+ 乳腺癌或實體瘤的臨床開發 1970-01-01T00:00:00-05:00January 1st, 1970| share this article!【財華社訊】亞盛醫藥-B(06855.HK)公布,公司在研原創新藥Bcl-2抑制劑APG-2575的臨床試驗申請獲美國食品藥品管理局(美國FDA)許可,將展開單藥或與抗癌藥物聯合治療晚期ER+乳腺癌或實體瘤的研究。 Read More share this article! Related Posts Chinese carmaker Chery banks on battery technology to rev up transition to EVs May 18th, 2024 Dow ends above 40,000 milestone, other indexes notch weekly gains May 17th, 2024 India: Wipro COO Amit Choudhary quits, business head Jain to take over May 17th, 2024 Haidilao restaurant operator Super Hi surges 46% on U.S. listing debut May 17th, 2024